Kevin P. Malobisky
Chief Operating Officer chez DBV TECHNOLOGIES
Profil
Kevin P.
Malobisky is the founder of Revelar Biotherapeutics, Inc. He is currently the Chief Operations Officer at DBV Technologies SA since 2023.
Previously, he worked as the SVP-Global Regulatory Affairs & Compliance at Achillion Pharmaceuticals, Inc. from 2018 to 2020.
From 2015 to 2016, he served as the Global Head-Regulatory & Quality at Zafgen, Inc. He also held the position of Senior Vice President-Regulatory Affairs & Quality at Karyopharm Therapeutics, Inc. from 2016 to 2018.
Additionally, he has experience as the Chief Regulatory & Strategic Operations Officer at Tavanta Therapeutics, Inc. Dr. Malobisky obtained his undergraduate degree from The Pennsylvania State University.
He holds a doctorate degree from Capella University LLC and a graduate degree from Temple University School of Pharmacy.
Postes actifs de Kevin P. Malobisky
| Sociétés | Poste | Début |
|---|---|---|
| DBV TECHNOLOGIES | Chief Operating Officer | 01/12/2023 |
Anciens postes connus de Kevin P. Malobisky
| Sociétés | Poste | Fin |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | Compliance Officer | 28/01/2020 |
| KARYOPHARM THERAPEUTICS INC. | General Counsel | 01/09/2018 |
| LARIMAR THERAPEUTICS, INC. | General Counsel | 01/08/2016 |
Tavanta Therapeutics, Inc.
 Tavanta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tavanta Therapeutics, Inc. operates as a clinical-stage pharmaceutical company developing a diverse pipeline of specialty drugs. The company is based in King of Prussia, PA and has subsidiaries in Hungary. Lynne M. Powell has been the CEO of the company since 2019. | Corporate Officer/Principal | - |
Revelar Biotherapeutics, Inc.
 Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | Founder | - |
Formation de Kevin P. Malobisky
| The Pennsylvania State University | Undergraduate Degree |
| Capella University LLC | Doctorate Degree |
| Temple University School of Pharmacy | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DBV TECHNOLOGIES | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Tavanta Therapeutics, Inc.
Tavanta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tavanta Therapeutics, Inc. operates as a clinical-stage pharmaceutical company developing a diverse pipeline of specialty drugs. The company is based in King of Prussia, PA and has subsidiaries in Hungary. Lynne M. Powell has been the CEO of the company since 2019. | Health Technology |
Revelar Biotherapeutics, Inc.
Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | Health Technology |
